微创医学

目的探讨替罗非班对急性心肌梗死PCI术后冠状动脉血流和血小板聚集率的影响。方法80例急诊PCI治疗的急性心肌梗死患者作为研究对象，随机均分为替罗非班组和对照组各40例，替罗非班组采取肝素联合替罗非班治疗，对照组采取肝素治疗，观察最终造影结果、肌酸激酶峰值浓度、90 min ST段下降幅度、术后左心室射血分数及并发症发生情况。结果两组冠状动脉血流TIMI分级比较，差异无统计学意义（P＞0.05）；替罗非班组校正TIMI计帧数明显低于对照组，差异有统计学意义（P＜0.05）；治疗前替罗非班组与对照组血小板聚集率对比，差异无统计学意义（P＞0.05）；治疗后替罗非班组与对照组和治疗前对比，血小板聚集率明显降低（P＜0.01）；治疗后对照组和治疗前对比，血小板聚集率明显降低（P＜0.01）。结论替罗非班对急性心肌梗死PCI术后冠状动脉血流有一定的影响，能够降低血小板聚集率，提高治疗效果。

ObjectiveTo explore the influence of tirofibanon on the coronary blood flow and platelet aggregation rate in patients with acute myocardium infarction after percutaneous coronary intervention(PCI). MethodsA total of 80 patients with acute myocardium infarction received PCI were randomly divided into tirofiban group and control group, 40 cases in each group.Patients in the tirofiban group were treated by heparin combine with tirofiban, and the patients in control group were treated by heparin. The eventually imaging results, peak concentration of creatine kinase, 90min ST descender, left ventricular ejection fraction and complicationsrate were compared. ResultsThere was no significant difference between the TIMI classification of coronary blood flow of the two groups(P＞0.05); The corrected TIMI frame counts of the tirofiban group were lower than those of the control group,the difference was statistically significant (P＜0.05); Before treatment, there was no significant difference between the platelet aggregation rate of the two groups; After treatment, the platelet aggregation rates of the two groups were lower than those before treatment, the differences were statistically significant (P＜0.01); After treatment, the platelet aggregation rate of the tirofiban group was significantly lower than that of the control group, the difference was statistically significant (P＜0.01) . ConclusionPCI can impact the coronary blood flow of patients with acute myocardial infarction, and decrease the platelet aggregation rate and improve the therapeutic effect.